Direkt zum Inhalt
Merck

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.

Nature communications (2015-04-01)
Shahul Hameed P, Suresh Solapure, Vikas Patil, Philipp P Henrich, Pamela A Magistrado, Sowmya Bharath, Kannan Murugan, Pavithra Viswanath, Jayashree Puttur, Abhishek Srivastava, Eknath Bellale, Vijender Panduga, Gajanan Shanbag, Disha Awasthy, Sudhir Landge, Sapna Morayya, Krishna Koushik, Ramanatha Saralaya, Anandkumar Raichurkar, Nikhil Rautela, Nilanjana Roy Choudhury, Anisha Ambady, Radha Nandishaiah, Jitendar Reddy, K R Prabhakar, Sreenivasaiah Menasinakai, Suresh Rudrapatna, Monalisa Chatterji, María Belén Jiménez-Díaz, María Santos Martínez, Laura María Sanz, Olivia Coburn-Flynn, David A Fidock, Amanda K Lukens, Dyann F Wirth, Balachandra Bandodkar, Kakoli Mukherjee, Robert E McLaughlin, David Waterson, Lyn Rosenbrier-Ribeiro, Kevin Hickling, V Balasubramanian, Peter Warner, Vinayak Hosagrahara, Adam Dudley, Pravin S Iyer, Shridhar Narayanan, Stefan Kavanagh, Vasan K Sambandamurthy
ZUSAMMENFASSUNG

The widespread emergence of Plasmodium falciparum (Pf) strains resistant to frontline agents has fuelled the search for fast-acting agents with novel mechanism of action. Here, we report the discovery and optimization of novel antimalarial compounds, the triaminopyrimidines (TAPs), which emerged from a phenotypic screen against the blood stages of Pf. The clinical candidate (compound 12) is efficacious in a mouse model of Pf malaria with an ED99 <30 mg kg(-1) and displays good in vivo safety margins in guinea pigs and rats. With a predicted half-life of 36 h in humans, a single dose of 260 mg might be sufficient to maintain therapeutic blood concentration for 4-5 days. Whole-genome sequencing of resistant mutants implicates the vacuolar ATP synthase as a genetic determinant of resistance to TAPs. Our studies highlight the potential of TAPs for single-dose treatment of Pf malaria in combination with other agents in clinical development.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Salzsäure, ACS reagent, 37%
Sigma-Aldrich
Salzsäure, ACS reagent, 37%
Sigma-Aldrich
Toluol, ACS reagent, ≥99.5%
Sigma-Aldrich
Chlorwasserstoff -Lösung, 4.0 M in dioxane
Sigma-Aldrich
Toluol, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
Aluminiumoxid, activated, basic, Brockmann I
Sigma-Aldrich
1,4-Dioxan, ACS reagent, ≥99.0%, contains ≤25 ppm BHT as stabilizer
Sigma-Aldrich
Salzsäure -Lösung, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Aluminiumoxid, activated, neutral, Brockmann I
Sigma-Aldrich
N,N-Diisopropylethylamin, 99.5%, biotech. grade
Sigma-Aldrich
Salzsäure, 37 wt. % in H2O, 99.999% trace metals basis
Sigma-Aldrich
Salzsäure, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
Chlorwasserstoff -Lösung, 2.0 M in diethyl ether
Sigma-Aldrich
Toluol, anhydrous, 99.8%
Sigma-Aldrich
1,4-Dioxan, ACS reagent, ≥99.0%
Sigma-Aldrich
Salzsäure, meets analytical specification of Ph. Eur., BP, NF, fuming, 36.5-38%
Sigma-Aldrich
1,4-Dioxan, suitable for HPLC, ≥99.5%
Supelco
Salzsäure -Lösung, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Di-tert-Butyldicarbonat, ReagentPlus®, 99%
Sigma-Aldrich
Aluminiumoxid, powder, 99.99% trace metals basis
Sigma-Aldrich
Aluminiumoxid, activated, acidic, Brockmann I
Sigma-Aldrich
N,N-Diisopropylethylamin, ReagentPlus®, ≥99%
Sigma-Aldrich
Aluminiumoxid, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
Chlorwasserstoff -Lösung, 1.0 M in diethyl ether
Sigma-Aldrich
Chlorwasserstoff, ReagentPlus®, ≥99%
Sigma-Aldrich
Toluol, ACS reagent, ≥99.5%
Sigma-Aldrich
Aluminiumoxid, nanoparticles, <50 nm particle size (DLS), 20 wt. % in isopropanol
Sigma-Aldrich
N,N-Diisopropylethylamin, purified by redistillation, 99.5%
Sigma-Aldrich
2-Methylpyridin, 98%
Sigma-Aldrich
Salzsäure -Lösung, ~6 M in H2O, for amino acid analysis